Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 10/20 | 0.42 |
| ▸ | TAB1 | Q15750 | 10/20 | 0.42 |
| ▸ | ITK | Q08881 | 4/20 | 0.40 |
| ▸ | AXL | P30530 | 3/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16945224 | 0.92 | ITK (0.39) | MAP3K7TAB1ITKAXLNTRK1 | |
| SCHEMBL18250455 | 0.92 | AXL (0.42) | MAP3K7TAB1ITKAXLNTRK1 | |
| SCHEMBL16945255 | 0.90 | KIT (0.45) | MAP3K7TAB1AXLNTRK1DYRK1A | |
| SCHEMBL18238418 | 0.90 | MAP3K7 (0.42) | MAP3K7TAB1ITKAXLNTRK1 | |
| SCHEMBL18250456 | 0.90 | MAP3K7 (0.42) | MAP3K7TAB1ITKAXLNTRK1 | |
| SCHEMBL16945226 | 0.90 | MAP3K7 (0.42) | MAP3K7TAB1ITKAXLNTRK1 | |
| SCHEMBL16945220 | 0.89 | PLCG1 (0.43) | MAP3K7TAB1ITKAXLNTRK1 | |
| SCHEMBL18250452 | 0.89 | SGK1 (0.40) | MAP3K7TAB1AXLNTRK1PIM1 | |
| SCHEMBL18239020 | 0.89 | PLCG1 (0.43) | MAP3K7TAB1ITKAXLNTRK1 | |
| SCHEMBL16945148 | 0.89 | KIT (0.49) | MAP3K7TAB1ITKAXLNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | TPMT, MALT1, IRAK4 | MAP3K7 152/4885TAB1 861/4885ITK 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.